期刊
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
卷 70, 期 6, 页码 1045-1049出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2014.01.905
关键词
atenolol; beta-blockers; hemangiomas; propranolol; randomized; treatment; trial
类别
Background: Infantile hemangiomas have a dramatic response to propranolol, a nonselective beta-blocker. However, this treatment is not risk-free and many patients are excluded because of respiratory comorbidities. Atenolol is a cardioselective beta-blocker that may have fewer adverse events. Objective: We sought to evaluate the effectiveness of atenolol against propranolol in a noninferiority trial. Methods: In all, 23 patients met the inclusion criteria and were randomized to receive either atenolol or propranolol. Thirteen patients were treated with atenolol and 10 with propranolol. Follow-up was made at baseline, 2 weeks, 4 weeks, and then monthly for 6 months. Results: Patients treated with atenolol had a complete response of 53.8% and 60% with propranolol, respectively. These results were nonsignificant (P = .68). Relevant adverse events were not reported. Limitations: The reduced number of patients could have influenced our results. Conclusion: Atenolol appears to be as effective as propranolol. We did not find significant differences between these results or any adverse events.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据